Additionally, a study of responders and non‐responders with melanoma receiving anti‐programmed cell death 1 protein (PD‐1) immunotherapy revealed both differentially abundant bacterial taxa and different functionality profiles between the groups based on metagenomics and pathway analysis (Gopalakrishnan et al., 2018). This evidence concerns the gene PDCD1 and melanoma.